Two independent, but interrelated conditions that have a growing impact on healthy life expectancy and health care costs in developed nations are the age related loss of muscle mass (sarcopenia) and obesity. Sarcopenia affects approximately one third of adults over 60 years of age and more than 50% of those over 80 years, which is of concern when one considers that the most rapidly expanding population demographic in the UK is adults \>80 years of age. Skeletal muscle is important in regulating blood glucose and insulin sensitivity. Thus, sarcopenia may play a role in exacerbating insulin resistance and progression toward Type II diabetes (T2D). Indeed, the highest incidence of T2D in the UK has been noted to occur in adults \>65 years. Obesity is a major risk factor for chronic diseases including T2D and cardiovascular disease. Progression towards obesity is associated with a concomitant decrease in muscle mass, producing an unfavorable ratio of fat to muscle. Thus, obesity in old age may exacerbate the progression of sarcopenia. For the proposed study the investigators will conduct preliminary laboratory tests to characterize body composition, insulin sensitivity, systemic inflammation, aerobic capacity and muscle protein metabolism (in the fasted and fed state) in healthy older and obese older adults for comparison against healthy young individuals.
Twenty healthy young (aged 18-35), healthy old and obese older adults (aged ≥65) will be recruited. Old groups will be matched for age and sexual dimorphism. Obese participants will be classed as prediabetic based on a fasting A1C between 5.7 and 6.4% and impaired fasting glucose between 5.6 and 6.9 mmol/L. Obese participants will habitually take between 2000-5000 steps per day, whilst healthy young and old participants will complete \>5000 steps per day. VISIT 1 Preliminary assessments - Over a 3day period, participants will be instructed to wear a portable pedometer, to allow visual feedback on step count, and an armband accelerometer to determine habitual daily energy expenditure and the intensity of physical activity. In addition, participants will log their dietary intake. VISIT 2 Body composition and metabolic profiling After consuming a standardized meal the previous evening, participants will report to the Wellcome Trust Clinical Research Facility in a 10 hour fasted state at approximately 09.00. Participants will be weighed in light clothing and blood pressure will be measured. Thereafter, body composition will be determined using dual energy Xray absorptiometry (DXA) and resting metabolic rate (RMR) via ventilated hood and continuous gas collection. Following RMR, a catheter will be inserted into a forearm vein and a resting, fasted blood sample obtained to determine postprandial insulin sensitivity using the HOMA-IR index. VISIT 3 Muscle protein metabolism Participants will return to the lab in a 10 hour fasted-state at approximately 07.00 having refrained from strenuous exercise for 48 hours previously. Catheters will be inserted into the antecubital vein of both forearms. A primed, continuous infusion of isotopically labeled amino acid will be infused into one arm and the other will be used for frequent blood sampling. Muscle biopsies will be obtained 3 and 7 hours into the infusion to determine postabsorptive and postprandial rates of muscle protein synthesis.
Study Type
OBSERVATIONAL
Enrollment
38
Myofibrillar protein synthesis rates via mass spectrometry
Postabsorptive and postprandial myofibrillar protein synthesis rates between groups and following the activity intervention
Time frame: 2 years
Muscle fibre properties via immunohistochemical staining
muscle fibre type (i.e. I and II) and cross sectional area
Time frame: 2 years
Muscle fibre lipid content immunofluorescent staining
Intramyocellular lipid content in Type I and II fibres
Time frame: 2 years
Physical activity levels via accelerometry
Daily average time spent in sedentary, light, moderate or vigorous intensity activity
Time frame: 2 years
Inflammation via plasma/insulin assays
Blood markers of inflammation, interleukin 6 and c-reactive protein
Time frame: 2 years
Insulin sensitivity via plasma assays
Blood samples will be analyzed for insulin, glucose and hbA1C for indication of whole-body insulin sensitivity
Time frame: 2 years
Body composition via dual x-ray absorptiometry
DXA-derived fat and fat free mass will be measured
Time frame: 2 years
Intramuscular signaling via western blot
Western blots for phosphorylation of key anabolic signaling proteins
Time frame: 2 years
Dietary intake via dietary logs
Diet logs will be assessed for total energy and macronutrient intake
Time frame: 2 years
Daily step count by pedometer
Average daily step count assessed via waist worn pedometer
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.